



(11) **EP 3 218 397 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 72**

(48) Corrigendum issued on:  
**07.04.2021 Bulletin 2021/14**

(45) Date of publication and mention  
of the grant of the patent:  
**24.02.2021 Bulletin 2021/08**

(21) Application number: **15797815.6**

(22) Date of filing: **13.11.2015**

(51) Int Cl.:  
**C07K 16/10 (2006.01)**

(86) International application number:  
**PCT/US2015/060733**

(87) International publication number:  
**WO 2016/077789 (19.05.2016 Gazette 2016/20)**

(54) **NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE**

NEUTRALISIERENDE ANTIKÖRPER GEGEN EBOLA VIRUS GLYKOPROTEIN UND DEREN  
VERWENDUNG

ANTICORPS NEUTRALISANTS CONTRE EBOLA GLYCOPROTEIN ET LEUR UTILISATION

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **14.11.2014 US 201462080094 P**  
**03.12.2014 US 201462087087 P**

(43) Date of publication of application:  
**20.09.2017 Bulletin 2017/38**

(60) Divisional application:  
**21158309.1**

(73) Proprietors:  

- **The United States Of America, As Represented By The Secretary, Department Of Health And Human Services**  
**Bethesda, MD 20852-7660 (US)**
- **The United States Government, as represented by The Secretary of The Army**  
**Fort Detrick, MD 21702 (US)**
- **Humabs Biomed S.A.**  
**6500 Bellinzona (CH)**
- **Institute for Research in Biomedicine**  
**6500 Bellinzona (CH)**

(72) Inventors:  

- **CORTI, Davide**  
**CH-6500 Bellinzona (CH)**
- **LANZAVECCHIA, Antonio**  
**CH-6500 Bellinzona (CH)**
- **TREFRY, John**  
**MD 210702 (US)**
- **SULLIVAN, Nancy**  
**MD 20892 (US)**
- **MULANGU, Sabue**  
**MD 20892 (US)**
- **GRAHAM, Barney**  
**MD 20892 (US)**
- **MUYEMBE-TAMFUN, Jean-Jacques**  
**Kinshasa (CG)**
- **LEDGERWOOD, Julie**  
**Bethesda, MD 20892 (US)**
- **STANLEY, Daphne**  
**Bethesda, MD 20892 (US)**

(74) Representative: **Docherty, Robert Charles**  
**Symbiosis IP Limited**  
**York Biotech Campus**  
**Office 14FA05**  
**Sand Hutton**  
**York, YO41 1LZ (GB)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 218 397 B8**

(56) References cited:

**WO-A2-2004/018649 WO-A2-2011/071574**

- **XIANGGUO QIU ET AL: "Characterization of glycoprotein-specific monoclonal antibodies", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 141, no. 2, 13 August 2011 (2011-08-13), pages 218-227, XP028322702, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2011.08.008 [retrieved on 2011-08-31]**

- **LEE J E ET AL: "Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD, GB, vol. 19, no. 4, 1 August 2009 (2009-08-01), pages 408-417, XP026541929, ISSN: 0959-440X, DOI: 10.1016/J.SBI.2009.05.004 [retrieved on 2009-06-24]**